RoyceDerm LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
At a glance: **FDA Warning Letter to RoyceDerm LLC (MARCS-CMS 734781, October 1, 2026)** The FDA Center for Drug Evaluation and Research identified RoyceDerm LLC's "Herpes Relief Cream" marketed at roycederm.com as an unapproved new drug in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act; the product claims to relieve herpes symptoms but lacks FDA approval and is not established as safe and effective. The FDA stated that unapproved OTC products for sexually transmitted infections present serious public health concerns because consumers may forgo appropriate medical care and unknowingly transmit infections, and required RoyceDerm to submit a written response within 15 business days detailing corrective actions.
Argus analysis
# FDA Warning Letter Analysis: RoyceDerm LLC
**Company and Violation**
RoyceDerm LLC, based in Sheridan, Wyoming, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026. The agency identified "Herpes Relief Cream," marketed through roycederm.com, as an unapproved new drug. FDA conducted a website review in July 2026 and determined the product violates federal law by claiming to relieve herpes symptoms without FDA approval. The agency emphasized particular concern: unapproved drugs for sexually transmitted infections pose serious public health risks because consumers may delay medical care, leading to complications including infertility and sepsis, while potentially transmitting infections unknowingly to partners.
**Regulatory Citations**
The violations center on sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)). These sections require that new drugs—products not generally recognized as safe and effective for their intended use—obtain FDA approval before marketing. Section 201(g)(1) (21 U.S.C. 321(g)(1)) defines the product as a drug based on claims in labeling and webpage content: "Herpes Relief Cream," "helps relieve symptoms," and "before/after" images of lesions. The FD&C Act recognizes no over-the-counter drugs for treating any STI; prescription oversight by licensed healthcare providers is legally required.
**Response Requirements and Industry Watch Points**
RoyceDerm has fifteen business days from receipt to submit written corrections to FDAAdvisory@fda.hhs.gov (reference 734781). Compliance officers monitoring similar product categories should expect FDA to escalate if the company does not promptly discontinue marketing claims. Potential next steps include product seizure or injunction. The warning letter was copied to Everymarket Inc., suggesting possible distributor involvement. Peer companies marketing topical products for dermatological conditions should review website language, product names, and imagery for unintended drug claims that might trigger similar enforcement action.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER RoyceDerm LLC MARCS-CMS 734781 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: RoyceDerm LLC 1309 Coffeen Avenue, Ste 3000 , WY Sheridan , WY 82801 United States service@roycederm.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 255 Primera Blvd, Ste 160 Lake Mary, FL 32746 WARNING LETTER Reference Number: 734781 To RoyceDerm LLC: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://roycederm.com/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “Herpes Relief Cream” product on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://roycederm.com/ in July 2026. Based on our review, “Herpes Relief Cream” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection wit…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has RoyceDerm LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for RoyceDerm LLC as of 2026-10-06. Argus ingests new FDA enforcement records daily.
- What FDA violations was RoyceDerm LLC cited for?
- The FDA Warning Letter to RoyceDerm LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs. Classification: Unapproved drug.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). RoyceDerm LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-roycederm-llc-2026-10-01-unapproved-drug
"RoyceDerm LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-roycederm-llc-2026-10-01-unapproved-drug.
Argus HQ Research. "RoyceDerm LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 8, 2026. https://argushq.ai/fda/warning-letter/fda-wl-roycederm-llc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_roycederm_llc_2026_10_01_unapproved_drug_2026,
title = {RoyceDerm LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-roycederm-llc-2026-10-01-unapproved-drug},
note = {Accessed: October 8, 2026}
}